Novo Nordisk’s Wegovy reduces risk of cardiovascular events
August 9, 2023Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …
Oculis announces positive results from phase 3 OPTIMIZE trial
August 9, 2023Research and Development Oculis, Opthalmology, clinical trial, eyedrops, ocular surgery
Oculis has announced positive topline results from its phase 3 OPTIMIZE trial for its OCS-01 eyedrops, a once daily, high …
FDA grants clearance to next phase of Ascentage Pharma’s clinical trial for CLL/SLL treatment
August 8, 2023Research and Development Ascentage Pharma, CLL/SLL, FDA, Oncology, clinical trial
Ascentage Pharma has announced that the US Food and Drug Administration (FDA) has granted clearance for the phase 3 study …
Astex expands collaboration with MSD
August 8, 2023Business Services Astex pharmaceuticals, Merck, Oncology, collaboration, small molecules
Astex Pharmaceuticals has announced an exclusive worldwide research collaboration and license agreement with MSD (known as Merck in the US), …
Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease
August 8, 2023Research and Development Cardiology, Vazkepa, cardiovascular disease, pharmaceutical
On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s treatment for people with cardiovascular …
First oral treatment for women with postpartum depression approved by FDA
August 7, 2023Research and Development FDA, postpartum depression, treatment, zurzuvae
On 4 August 2023, the US Food and Drug Administration (FDA) approved the use of Zurzuvae for adults with postpartum …
New vaccine research centre opened to prepare for future pandemics
August 7, 2023Research and Development Immunology, UKHSA, pandemic, vaccine research centre
Ministers have opened a new vaccine research centre at the UK Health and Security Agency’s (UKHSA) Porton Down campus in …
Astellas announces FDA approval for Izervay for GA treatment
August 7, 2023Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy
Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …
FDA approves Merck’s Ervebo vaccine for under 18s
August 4, 2023Research and Development FDA, Immunology, Vaccine, ebolavirus
On 3 August 2023, the US Food and Drug Administration (FDA) approved Merck’s Ervebo vaccine for children over 12 months. …
Evox Therapeutics enters agreement for next generation gene therapy for heart disease
August 4, 2023Research and Development Cardiology, Evox Therapeutics, Icahn Mount Sinai, cvd, gene therapy
Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn …
Ionis and Novartis partner for CVD treatment programme
August 4, 2023Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd
Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …
Targeted chemotherapy to kill all solid tumours developed in preclinical research
August 3, 2023Research and Development Cancer, Oncology, chemotherapy, pharmaceutical, tumour
Researchers from the City of Hope organisation in the US have released a study confirming the development of AOH1996, a …
FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment
August 3, 2023Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho
Taiho Oncology and Taiho Pharmaceutical have announced that the US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil) as …
FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma
August 3, 2023Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma
ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …
Biopharmaceutical company EQRx set to be acquired by Revolution Medicines
August 2, 2023Research and Development EQRx, Pharmacy, biopharmaceutical, pharmaceutical, revolution medicines
On 1 August 2023, Revolution Medicines signed an official agreement confirming the acquisition of the biopharmaceutical company EQRx. The deal …
Proof-of-concept study shows non-invasive brain stimulation efficient as treatment for ADHD in children
August 2, 2023Research and Development ADHD, Hebrew University of Jerusalem, Psychiatry, brain stimulation, clinical trial, university of surrey
Researchers from the University of Surrey, UK, and the Hebrew University of Jerusalem, Israel, have found that non-invasive brain stimulation …
MyMD reports statistically significant results from phase 2 trial for sarcopenia/age-related frailty
August 2, 2023Research and Development Musculo-skeletal disorder, MyMD, clinical trial, sarcopenia
MyMD Pharmaceuticals has announced statistically significant positive topline results from a phase 2 trial of oral TNF- α inhibitor, MYMD-1 …
The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19
August 1, 2023Research and Development COVID-19, Infections and infestations, NIH, clinical trials, long covid
As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials of its ‘Researching COVID to …
Merck shares data from phase 3 trial for breast cancer treatment
August 1, 2023Research and Development MSD, Merck, Oncology, breast cancer, keytruda
Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …
GSK’s Jemperli approved for treatment of endometrial cancer
August 1, 2023Research and Development FDA, GSK, Jemperli, Oncology, dostarlimab, endometrial cancer
GSK has announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
